ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3

计划入组 750 人 · 首次发布于 2024 年 12 月 4 日

ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2

计划入组 69 人 · 首次发布于 2020 年 7 月 13 日

EFFECTIVENESS AND SAFETY OF CREAM CONTAINING SPENT GRAIN WAX EXTRACT, ARGAN OIL, AND SHEA BUTTER POST-TRICHOLOROACETIC ACID 15% PEEL: RANDOMIZED, CONTROLLED, DOUBLE-BLIND, SPLIT-FACE CLINICAL TRIAL

计划入组 27 人 · 首次发布于 2024 年 2 月 13 日

RhoA Y42C(Revere)

Thyme Extract/Hedera Extract

CAAX-2 (Celera-Genomics)

Reheva Biosciences, Inc.

United States

Aegera Therapeutics, Inc.

Canada

NEMERA LA VERPILLIERE

France

Rezera's Oral NLRP3 Inhibitor Ruvonoflast Hits Primary Inflammation Endpoint in Phase 2 RESOLVE-1, Phase 3 PAD Trial Planned for 2027

REMORA Trial: Integrating Symptom Tracking App into Rheumatoid Arthritis Care

Reverb Therapeutics Secures $12M Seed Funding to Advance Novel Cytokine-Targeting Platform